nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—F2—urine—nephrolithiasis	0.0926	0.201	CbGeAlD
Dabigatran etexilate—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0319	0.0667	CcSEcCtD
Dabigatran etexilate—UGT1A9—renal system—nephrolithiasis	0.0313	0.0682	CbGeAlD
Dabigatran etexilate—UGT1A9—kidney—nephrolithiasis	0.0303	0.0659	CbGeAlD
Dabigatran etexilate—CES2—nephron tubule—nephrolithiasis	0.0278	0.0604	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—nephrolithiasis	0.0253	0.0549	CbGeAlD
Dabigatran etexilate—CES2—renal system—nephrolithiasis	0.0253	0.0549	CbGeAlD
Dabigatran etexilate—NQO2—nephron tubule—nephrolithiasis	0.0248	0.054	CbGeAlD
Dabigatran etexilate—UGT2B7—kidney—nephrolithiasis	0.0244	0.0531	CbGeAlD
Dabigatran etexilate—CES2—kidney—nephrolithiasis	0.0244	0.0531	CbGeAlD
Dabigatran etexilate—CES2—cortex of kidney—nephrolithiasis	0.0238	0.0517	CbGeAlD
Dabigatran etexilate—F2—renal system—nephrolithiasis	0.0226	0.0493	CbGeAlD
Dabigatran etexilate—NQO2—renal system—nephrolithiasis	0.0226	0.0491	CbGeAlD
Dabigatran etexilate—F2—kidney—nephrolithiasis	0.0219	0.0476	CbGeAlD
Dabigatran etexilate—NQO2—kidney—nephrolithiasis	0.0218	0.0475	CbGeAlD
Dabigatran etexilate—NQO2—cortex of kidney—nephrolithiasis	0.0212	0.0462	CbGeAlD
Dabigatran etexilate—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.0186	0.0389	CcSEcCtD
Dabigatran etexilate—Gout—Hydrochlorothiazide—nephrolithiasis	0.018	0.0376	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.017	0.0355	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.0153	0.0321	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.0152	0.0317	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.0122	0.0255	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.0122	0.0255	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0235	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0233	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.011	0.0229	CcSEcCtD
Dabigatran etexilate—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0225	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0225	CcSEcCtD
Dabigatran etexilate—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.0105	0.022	CcSEcCtD
Dabigatran etexilate—Influenza—Hydrochlorothiazide—nephrolithiasis	0.0105	0.022	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.0103	0.0214	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00979	0.0205	CcSEcCtD
Dabigatran etexilate—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00945	0.0197	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00926	0.0194	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00921	0.0192	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00913	0.0191	CcSEcCtD
Dabigatran etexilate—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00896	0.0187	CcSEcCtD
Dabigatran etexilate—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00886	0.0185	CcSEcCtD
Dabigatran etexilate—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00881	0.0184	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00831	0.0174	CcSEcCtD
Dabigatran etexilate—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00723	0.0151	CcSEcCtD
Dabigatran etexilate—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0071	0.0148	CcSEcCtD
Dabigatran etexilate—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00679	0.0142	CcSEcCtD
Dabigatran etexilate—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00671	0.014	CcSEcCtD
Dabigatran etexilate—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00658	0.0138	CcSEcCtD
Dabigatran etexilate—UGT2B15—Phase II conjugation—SLC26A1—nephrolithiasis	0.00658	0.106	CbGpPWpGaD
Dabigatran etexilate—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00649	0.0136	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00645	0.0135	CcSEcCtD
Dabigatran etexilate—Cough—Hydrochlorothiazide—nephrolithiasis	0.00641	0.0134	CcSEcCtD
Dabigatran etexilate—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00625	0.0131	CcSEcCtD
Dabigatran etexilate—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00625	0.0131	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00599	0.0125	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—SLC2A9—nephrolithiasis	0.0059	0.0955	CbGpPWpGaD
Dabigatran etexilate—Shock—Hydrochlorothiazide—nephrolithiasis	0.0059	0.0123	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00587	0.0123	CcSEcCtD
Dabigatran etexilate—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.0056	0.0117	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00546	0.0114	CcSEcCtD
Dabigatran etexilate—ABCB1—nephron tubule—nephrolithiasis	0.00536	0.0117	CbGeAlD
Dabigatran etexilate—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00534	0.0112	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00527	0.011	CcSEcCtD
Dabigatran etexilate—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00517	0.0108	CcSEcCtD
Dabigatran etexilate—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00512	0.0107	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.0049	0.0102	CcSEcCtD
Dabigatran etexilate—ABCB1—renal system—nephrolithiasis	0.00487	0.0106	CbGeAlD
Dabigatran etexilate—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00476	0.00995	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00474	0.0099	CcSEcCtD
Dabigatran etexilate—ABCB1—kidney—nephrolithiasis	0.00471	0.0102	CbGeAlD
Dabigatran etexilate—ABCB1—cortex of kidney—nephrolithiasis	0.00459	0.00998	CbGeAlD
Dabigatran etexilate—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00441	0.00923	CcSEcCtD
Dabigatran etexilate—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0043	0.00898	CcSEcCtD
Dabigatran etexilate—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00886	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.0041	0.00857	CcSEcCtD
Dabigatran etexilate—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00396	0.00828	CcSEcCtD
Dabigatran etexilate—UGT2B15—Biological oxidations—SLC26A1—nephrolithiasis	0.00385	0.0622	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00796	CcSEcCtD
Dabigatran etexilate—Rash—Hydrochlorothiazide—nephrolithiasis	0.00378	0.00789	CcSEcCtD
Dabigatran etexilate—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00377	0.00789	CcSEcCtD
Dabigatran etexilate—Headache—Hydrochlorothiazide—nephrolithiasis	0.00375	0.00784	CcSEcCtD
Dabigatran etexilate—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00356	0.00744	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—SLC2A9—nephrolithiasis	0.00348	0.0563	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Phase II conjugation—SLC26A1—nephrolithiasis	0.003	0.0484	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00261	0.0421	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Phase II conjugation—SLC26A1—nephrolithiasis	0.00243	0.0394	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC2A9—nephrolithiasis	0.002	0.0323	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—SLC26A1—nephrolithiasis	0.00175	0.0283	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC2A9—nephrolithiasis	0.00162	0.0263	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00157	0.0253	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—SLC26A1—nephrolithiasis	0.00142	0.023	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0014	0.0227	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00137	0.0222	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00136	0.022	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00113	0.0183	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00101	0.0164	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GRHPR—nephrolithiasis	0.000868	0.014	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AGXT—nephrolithiasis	0.000774	0.0125	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00075	0.0121	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SLC7A9—nephrolithiasis	0.000707	0.0114	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—DGKH—nephrolithiasis	0.000707	0.0114	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000661	0.0107	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC26A1—nephrolithiasis	0.000658	0.0106	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APRT—nephrolithiasis	0.000658	0.0106	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RGS14—nephrolithiasis	0.0006	0.00971	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000571	0.00924	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTH—nephrolithiasis	0.000522	0.00845	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AQP1—nephrolithiasis	0.000469	0.00758	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000447	0.00722	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CHRM3—nephrolithiasis	0.000424	0.00686	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADCY10—nephrolithiasis	0.000417	0.00674	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000415	0.00672	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000415	0.00672	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—DGKH—nephrolithiasis	0.000405	0.00656	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GRHPR—nephrolithiasis	0.000396	0.0064	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00037	0.00599	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RGS14—nephrolithiasis	0.000355	0.00573	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AGXT—nephrolithiasis	0.000353	0.0057	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000339	0.00547	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000339	0.00547	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000323	0.00522	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GRHPR—nephrolithiasis	0.000321	0.0052	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APRT—nephrolithiasis	0.0003	0.00485	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC26A1—nephrolithiasis	0.0003	0.00485	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PTH—nephrolithiasis	0.000295	0.00477	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000293	0.00474	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AGXT—nephrolithiasis	0.000286	0.00463	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTH—nephrolithiasis	0.000268	0.00434	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000257	0.00415	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000257	0.00415	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APRT—nephrolithiasis	0.000244	0.00394	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC26A1—nephrolithiasis	0.000244	0.00394	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DGKH—nephrolithiasis	0.00024	0.00387	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00024	0.00387	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000239	0.00386	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000239	0.00386	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AQP1—nephrolithiasis	0.000214	0.00345	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000213	0.00344	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000213	0.00344	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CHRM3—nephrolithiasis	0.000193	0.00312	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AQP1—nephrolithiasis	0.000174	0.00281	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CHRM3—nephrolithiasis	0.000173	0.0028	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00017	0.00275	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTH—nephrolithiasis	0.000158	0.00256	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CHRM3—nephrolithiasis	0.000157	0.00254	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000147	0.00238	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000131	0.00212	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000112	0.00181	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APRT—nephrolithiasis	0.000112	0.00181	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AQP1—nephrolithiasis	7.96e-05	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—nephrolithiasis	7.95e-05	0.00129	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CHRM3—nephrolithiasis	7.2e-05	0.00116	CbGpPWpGaD
